Candriam S.C.A. Immunocore Holdings PLC Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Candriam S.C.A. holds 140,006 shares of IMCR stock, worth $4.57 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

140,006

Previous 313,423 55.33%

Holding current value

$4.57 Million

Previous $10.6 Million 58.97%

% of portfolio

0.03%

Previous 0.07%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$30.06 - $41.49 $5.21 Million - $7.2 Million	-173,417 Reduced 55.33%	140,006 $4.36 Million
Q2 2024 Aug 05, 2024	BUY	$33.78 - $63.75 $4.2 Million - $7.93 Million	124,417 Added 65.83%	313,423 $10.6 Million
Q1 2024 May 03, 2024	BUY	$60.14 - $75.36 $2.71 Million - $3.39 Million	45,000 Added 31.25%	189,006 $12.3 Million
Q4 2023 Feb 14, 2024	SELL	$42.85 - $69.5 $6.38 Million - $10.4 Million	-149,005 Reduced 50.85%	144,006 $9.84 Million
Q3 2023 Nov 13, 2023	SELL	$49.5 - $66.6 $2.82 Million - $3.8 Million	-57,003 Reduced 16.29%	293,011 $15.2 Million
Q2 2023 Aug 08, 2023	BUY	$48.54 - $61.64 $1.57 Million - $1.99 Million	32,254 Added 10.15%	350,014 $21 Million
Q1 2023 May 12, 2023	BUY	$46.12 - $65.71 $9.16 Million - $13.1 Million	198,685 Added 166.86%	317,760 $15.7 Million
Q4 2022 Feb 13, 2023	SELL	$45.51 - $65.08 $11,240 - $16,074	-247 Reduced 0.21%	119,075 $6.8 Million
Q3 2022 Nov 10, 2022	BUY	$37.34 - $57.44 $4.46 Million - $6.85 Million	119,322 New	119,322 $5.6 Million

Others Institutions Holding IMCR

# of Institutions

140

Shares Held

41.4M

Call Options Held

139K

Put Options Held

299K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.43B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account